Mounjaro KwikPen Approved in UK; Biocorp Receives 510(K) Clearance for SoloSmart; Novo Initiates Second Ph3 Cagrisema T2DM Trial; Mounjaro 12.5mg Added to FDA Shortage Database; Counterfeit Ozempic Causes Cases of Hypoglycemia

Five cardiometabolic-related news items have been observed from Lilly, Biocorp, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.